Lung cancer drug trial stopped early — too few patients to know if it works
NCT ID NCT04926831
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug capmatinib in people with early-stage non-small cell lung cancer that has a specific genetic change (MET mutation). The goal was to see if taking the drug before and after surgery could improve outcomes. However, the trial was stopped early after enrolling only 4 participants, so no meaningful conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
capmatinib (a targeted cancer pill)
What this could lead to
If it worked, this could point toward a treatment that shrinks lung tumors before surgery and delays recurrence afterward.
What could go wrong
The trial was terminated early with only 4 participants, so we have very little data. It is unclear if capmatinib is effective or safe in this setting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fairfax Northern Virginia Hem Onc
Fairfax, Virginia, 22031, United States
-
Fairfax Northern Virginia Hem Onc .
Fairfax, Virginia, 22031, United States
-
UCLA Oncology Hematology
La Jolla, California, 92037, United States
-
UCLA Oncology Hematology .
La Jolla, California, 92037, United States
-
University of California Davis Cancer Center
Sacramento, California, 95817, United States
-
University of California Davis Cancer Center .
Sacramento, California, 95817, United States